Palvella Therapeutics, Inc.
PVLA
$23.44
-$1.13-4.60%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 154.25% | 311.38% | 49.90% | 17.82% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 208.33% | 225.95% | -33.30% | -47.56% | |
| Operating Income | -208.33% | -225.95% | 33.30% | 47.56% | |
| Income Before Tax | -119.24% | -139.23% | -154.21% | -781.71% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -119.24% | -139.23% | -154.21% | -781.71% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -119.24% | -139.23% | -154.21% | -781.71% | |
| EBIT | -208.33% | -225.95% | 33.30% | 47.56% | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | -127.71% | -130.32% | -343.79% | -620,200.00% | |
| Normalized Basic EPS | -2.54% | -139.27% | -154.22% | -781.23% | |
| EPS Diluted | -127.71% | -130.32% | -346.23% | -620,200.00% | |
| Normalized Diluted EPS | -2.54% | -139.27% | -155.32% | -781.23% | |
| Average Basic Shares Outstanding | 92.52% | 0.00% | 0.00% | 0.00% | |
| Average Diluted Shares Outstanding | 92.52% | 0.00% | -2.00% | 0.00% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |